HER2 breast cancer therapies: a review.
Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have been shown to be associated with poorer outcomes compared to 'HER2 normal' breast cancer. Research has focused on developing therapies directed to the HER2 receptor and its pathway. These include the monoclonal antibody trastuzumab, which has improved outcomes when used in patients with both advanced and early breast cancer. Lapatinib is a small-molecule tyrosine kinase inhibitor which has demonstrated activity in advanced breast cancer and is currently being evaluated in early stage disease. We discuss the therapeutic rationale and clinical trial experience with these agents. Other novel and emerging strategies targeting the HER2 receptor and its pathway are also discussed. These strategies include novel HER2 antibodies and small-molecule inhibitors, antibody-drug conjugates, agents targeting downstream components of the HER2 signaling pathway, and heat shock protein 90 (HSP90) inhibitors.
Murphy
Conleth G
CG
Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. murpphyc@mskcc.org
Modi
Shanu
S
J Clin Oncol. 2001 May 15;19(10):2587-95
11352950
J Clin Oncol. 2005 Aug 10;23(23):5305-13
15955900
N Engl J Med. 2005 Oct 20;353(16):1673-84
16236738
J Clin Oncol. 1999 Sep;17(9):2639-48
10561337
Ann Oncol. 2008 Jun;19(6):1068-74
18283035
J Clin Oncol. 1996 Mar;14(3):737-44
8622019
Clin Cancer Res. 2007 Mar 15;13(6):1769-74
17363531
J Natl Cancer Inst. 2004 May 19;96(10):759-69
15150304
Cancer Res. 2006 Feb 1;66(3):1630-9
16452222
Ann Oncol. 2009 Jun;20(6):1026-31
19179558
Science. 1987 Jan 9;235(4785):177-82
3798106
Cancer Res. 1990 Mar 1;50(5):1550-8
1689212
Adv Exp Med Biol. 2003;532:253-68
12908564
J Clin Oncol. 2005 Nov 1;23(31):7811-9
16258083
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14536-41
8962087
J Clin Oncol. 2007 Aug 10;25(23):3525-33
17687157
J Natl Cancer Inst. 2007 Apr 18;99(8):628-38
17440164
J Clin Oncol. 1993 Oct;11(10):1936-42
8105035
Int J Oncol. 2007 Oct;31(4):769-76
17786307
Cancer Cell. 2007 Oct;12(4):395-402
17936563
Cancer Res. 2004 Jun 1;64(11):3981-6
15173011
Curr Top Med Chem. 2006;6(11):1205-14
16842157
N Engl J Med. 1987 Oct 8;317(15):955-7
3627214
Clin Breast Cancer. 2004 Jun;5(2):142-7
15245619
Clin Cancer Res. 2007 Aug 15;13(16):4909-19
17699871
Clin Cancer Res. 2002 May;8(5):986-93
12006510
Clin Cancer Res. 2007 Mar 15;13(6):1775-82
17363532
J Clin Oncol. 2003 Aug 1;21(15):2889-95
12885806
J Clin Oncol. 1989 Aug;7(8):1120-8
2569032
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6087-93
17062684
Oncogene. 2004 Jan 22;23(3):646-53
14737100
Cardiovasc Toxicol. 2007;7(2):114-21
17652815
Lancet. 2007 Jan 6;369(9555):29-36
17208639
Clin Cancer Res. 2005 May 1;11(9):3385-91
15867239
Science. 1989 May 12;244(4905):707-12
2470152
J Natl Cancer Inst. 2008 Aug 6;100(15):1092-103
18664652
Cancer Res. 2008 Nov 15;68(22):9280-90
19010901
Cancer Cell. 2004 Apr;5(4):317-28
15093539
Oncogene. 2005 Sep 15;24(41):6213-21
16091755
Oncogene. 2002 Feb 14;21(8):1159-66
11850835
J Clin Oncol. 1998 Aug;16(8):2659-71
9704716
J Clin Oncol. 2005 Feb 20;23(6):1078-87
15718306
Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s
11916237
J Clin Oncol. 2005 Nov 1;23(31):7820-6
16258084
Breast Cancer Res. 2006;8(6):215
17096862
Mol Cancer Ther. 2002 Jul;1(9):707-17
12479367
J Clin Oncol. 2002 Feb 1;20(3):719-26
11821453
J Clin Oncol. 2007 Dec 1;25(34):5410-7
18048823
J Clin Oncol. 2005 Jul 1;23(19):4265-74
15911866
Expert Opin Biol Ther. 2002 Jan;2(1):3-24
11772336
Cancer Chemother Pharmacol. 2008 Mar;61(3):509-14
17516068
Invest New Drugs. 2005 Jan;23(1):39-49
15528979
Immunol Lett. 2008 Mar 15;116(2):126-40
18201769
N Engl J Med. 2006 Feb 23;354(8):809-20
16495393
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9
1350088
Oncogene. 2002 Sep 12;21(41):6255-63
12214266
Clin Breast Cancer. 2008 Oct;8(5):453-6
18952561
Breast Cancer Res Treat. 2008 Dec;112(3):533-43
18188694
J Clin Oncol. 2007 Aug 1;25(22):3246-50
17577021
N Engl J Med. 2006 Dec 28;355(26):2733-43
17192538
Exp Hematol. 1999 Oct;27(10):1533-41
10517495
J Clin Oncol. 2007 Sep 1;25(25):3853-8
17679724
J Clin Oncol. 2002 Apr 1;20(7):1800-8
11919237
Mol Cancer Ther. 2001 Dec;1(2):85-94
12467226
Mol Biol Cell. 2004 Dec;15(12):5268-82
15385631
Semin Oncol. 2001 Oct;28(5 Suppl 16):4-11
11706390
J Clin Oncol. 2005 Mar 20;23(9):1885-93
15774780
N Engl J Med. 2005 Oct 20;353(16):1659-72
16236737
Nature. 2002 Mar 21;416(6878):279-80
11907566
N Engl J Med. 2001 Mar 15;344(11):783-92
11248153
Expert Rev Anticancer Ther. 2008 Dec;8(12):1883-90
19046108
Cancer Cell. 2004 Aug;6(2):117-27
15324695
Cancer. 2003 Jun 15;97(12):2972-7
12784331
J Clin Oncol. 2010 Jun 1;28(16):2698-704
20421541
J Clin Oncol. 2008 Jun 20;26(18):2999-3005
18458039
J Clin Oncol. 2008 Dec 1;26(34):5544-52
18955454
J Clin Oncol. 2005 Jun 20;23(18):4152-61
15961763